ACTRN12622001065785尚未招募1 期
Part A: An Open-Label, Single and Multiple-Dose Study to Evaluate Safety, Tolerability and Efficacy of ABI-2280 Vaginal Tablet in Participants with biopsy-confirmed Cervical Squamous Intraepithelial neoplasia (with visible lesions)
Antiva Bioscience, Inc.0 个研究点目标入组 9 人开始时间: 2022年8月2日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 25 Years 至 55 Years（—）
- 性别
- Female
入选标准
- •1. Women, 25 to 55 years old.
- •2. Participants with biopsy-confirmed CIN (with visible lesions) regardless of p16 positivity may be enrolled upon consultation with PI and medical Monitor. These participants will not be required to get large loop excision of the transformation zone (LLETZ) if not medically necessary, as determined by the PI in consultation with the Medical Monitor.
- •3. No prior treatment for Cervical intraepithelial neoplasia (CIN).
- •4. Generally, in good health with no clinically significant pulmonary, cardiac, gastro-enterologic, neurologic, renal, musculoskeletal, rheumatologic, metabolic, neoplastic, or endocrine disease.
- •5. Willing to use abstinence during the week(s) of study medication administration. In addition, participants agree to take additional strict precautions throughout the study to prevent pregnancy. Under the guidance of the PI, they will be informed of reliable birth control methods to include oral contraceptives and long-acting reversible contraceptive methods. IUDs are acceptable but should be inserted at least 1 month prior to enrollment; however, the use of contraception methods such as a diaphragm, spermicide or Nuvaring® are not allowed.
- •6. Agree to abstain from activities such as vaginal douching or insertion of any vaginal products other than the investigational product for at least 48 hours prior to enrollment through 7 days after last dose.
- •7. Generally experiencing regular menstrual cycles (as judged by the PI), unless using long-acting reversible contraception that induces amenorrhea (e.g., Mirena IUD, Norplant).
- •8. Able and willing to return to the clinic for all study procedures.
- •9. Able and willing to provide informed consent.
- •10. Colposcopy is satisfactory based on visualization of the entire squamocolumnar junction (SCJ). The borders of all lesions must be completely visible.
- •11. If cytology or previous histology suggests the presence of glandular disease, willing to undergo endocervical curettage (ECC) to rule out adenocarcinoma in situ or invasive cancer.
- •12. The upper limit of the visible (usually aceto-white) lesion is within 3 quadrants or less at screening.
- •13. Willing to provide access to medical records consisting of HPV test results and pathology reports including p16 results.
- •14. Able and willing to abstain from sexual intercourse for 48 hours prior to first dose and 48 hours after each dose.
排除标准
- •1. Women who are pregnant, plan to become pregnant in the next 4 months, or lactating females.
- •2. Unwilling to use stringent methods of contraception (including barrier method, as well as another acceptable method) throughout the course of the study.
- •3. History of cancer, except basal cell or squamous cell carcinoma of the skin.
- •4. History of genital herpes with outbreak within prior 12 months.
- •5. Have an active pelvic or non-HPV (Human papillomavirus) vaginal infection (e.g., that was detected by a positive urine screen for gonorrhea or chlamydial infection, bimanual exam consistent with pelvic inflammatory disease, positive bedside testing criteria for bacterial vaginosis, candida vaginitis or trichomonal vaginitis, etc).
- •6. Current or recent abnormal vaginal discharge and /or abnormal vaginal bleeding.
- •7. Had a therapeutic abortion or miscarriage less than 3 months prior.
- •8. Any clinically significant immune suppressing condition.
- •9. Any medical condition that, in the opinion of the Investigator, would result in increased risk of bleeding at biopsy.
- •10. Participants with a significant acute condition or any other condition that in the opinion of the Investigator might interfere with the evaluation of the study objectives.
- •11. Taking any of the following medications: corticosteroids (inhaled and topical corticosteroids are allowed), immunomodulatory treatments, any prescription that in the opinion of the Investigator could interfere with the interpretation of the results or over the counter (OTC) intravaginal preparation within 2 weeks of enrollment (Study Day 1).
- •12. Hypersensitivity to any component of the product formulation excipients and/or other nucleoside analogues (such as cidofovir, etc.).
- •13. Participation in any clinical study with an experimental medication or device within 30 days or 5 half-lives (whichever is longer) of enrollment (Study Day 1).
- •14. Human immunodeficiency virus (HIV) positive (tested at screening visit or tested within 3 months of screening visit).
- •15. Menses expected to start within 7 days of enrollment (Study Day 1).
- •16. Vaccination (even 1 dose) with a prophylactic HPV vaccine (i.e. Gardasil®, Gardasil®-9 or Cervarix®) in the last 3 months.
- •17. Vaccination with a therapeutic HPV vaccine.
- •18. Biopsy performed more than 60 days prior to enrollment (dosing), unless approved by the Medical Monitor.
- •19. CIN not amenable to adequate colposcopic evaluations.
- •20. Women who, in the PI’s judgment, would be harmed by the delay in undergoing definitive treatment as a result of study participation and the ABI-2280 Vaginal Tablet dosing schedule.
- •21. Resolution of CIN lesion(s) prior to enrollment.
- •22. ECC positive for glandular disease (adenocarcinoma in situ) or invasive cancer.
- •23. History of cervical cancer, colposcopy suspicious for cancer, any prior treatment of CIN, or hysterectomy.
- •24. Plan to have excision or ablation of the lesions, or to undergo LLETZ before the end of the study.
- •25. Current alcohol or substance abuse as assessed by the PI.
研究者
相似试验
招募中
不适用
Phase I clinical trial to investigate the safety, tolerability and pharmacokinetics of NewGenNafamostat in healthy male subjectsCertain infectious and parasitic diseasesKCT0005647ewGen Therapeutics32
终止
1 期
Safety, tolerability and pharmacokinetics of extended release formulations of ATN-249 in healthy volunteers when dosed once a day or over several daysInflammatory and Immune System - Normal development and function of the immune systemHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersCardiovascular - Other cardiovascular diseasesSkin - Other skin conditionsHereditary AngioedemaACTRN12618001417279ifeSci Pharmaceuticals, inc.6
进行中（未招募）
1 期
A study to find out the safety, tolerability and processing of RO7204239 by the body, the effect of RO7204239 on the body in participants with high body weightHealthy volunteersISRCTN10993304F. Hoffmann-La Roche Ltd36
进行中（未招募）
1 期
Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell DiseaseSickle Cell DiseaseEUCTR2016-004209-15-GBGlobal Blood Therapeutics, Inc.148
已完成
2 期
Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell DiseaseSickle Cell, Anemia, Hemolytic, Congenital, Hematologic DiseasesSickle Cell DiseaseLBCTR2019090195Global Blood Therapeutics Inc.38